Sarepta Therapeutics (SRPT) Q4 2025 earnings summary

Executive summary

• Entered 2026 with strong financial footing, four marketed therapies, $954 million in cash and investments, and a robust product pipeline, following decisive cost actions and debt restructuring in 2025.

• ELEVIDYS launched in Japan in February 2026, triggering a $40 million milestone; over 1,200 patients treated globally.

• Positive three-year EMBARK results for ELEVIDYS showed durable, statistically significant, and clinically meaningful efficacy in Duchenne muscular dystrophy.

• Base business delivered full-year GAAP and non-GAAP operating profit and positive cash flow, excluding collaboration and restructuring charges.

• CEO announced intention to retire by end of 2026, with a search for a successor underway.

Financial highlights

• 2025 total revenues reached $2.2 billion, up 16% year-over-year, with $1.86 billion in net product revenue and $334 million from collaborations and royalties.

• PMO franchise generated $965.6 million in 2025, with Q4 PMO revenues stable year-over-year and adherence rates exceeding 90%.

• ELEVIDYS contributed $898.7 million in 2025, with Q4 revenue at $110.4 million, impacted by flu season and rescheduled infusions.

• GAAP operating loss for 2025 was $700 million; non-GAAP operating loss was $492 million, both impacted by Arrowhead collaboration and restructuring charges.

• Cost restructuring initiatives delivered $285 million in operating expense savings from initial 2025 guidance midpoint.

Outlook and guidance

• 2026 net product revenue guidance is $1.2 billion–$1.4 billion; collaboration, contract manufacturing, and royalty revenues expected at $450 million–$550 million.

• Combined non-GAAP R&D and SG&A expenses projected at $800 million–$900 million; GAAP at $925 million–$1.075 billion.

• 2026 gross margins expected in the high 70% range, with improved margin profile due to lower production volumes.

• Cash flow expected to remain positive, with continued investment in pipeline and commercial initiatives.

• PMO revenue expected to decline modestly due to ELEVIDYS cannibalization; commercial initiatives anticipated to impact demand in 2H 2026 and beyond.